Literature DB >> 20935019

Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice.

Nigel D Toussaint1, Eugenie Pedagogos, Jennifer Beavis, Gavin J Becker, Kevan R Polkinghorne, Peter G Kerr.   

Abstract

BACKGROUND: Although clinical guidelines exist for optimal levels of serum markers of chronic kidney disease mineral and bone disorder (CKD-MBD), target parameters are not achieved in many haemodialysis (HD) patients. The reason for this evidence-practice gap is unclear and more information from patients and healthcare professionals is required to improve knowledge transfer. We aimed to determine potential barriers by surveying HD patients and staff about awareness and management of CKD-MBD.
METHODS: A total of 136 prevalent HD patients, 25 nephrologists and 58 dialysis nurses/technicians were surveyed. Three separate questionnaires included issues of knowledge and awareness of CKD-MBD and factors limiting management (including compliance, medications and general understanding).
RESULTS: Of patients surveyed, 84% had heard of phosphate, but 42% were unsure of high phosphate foods and 46% unaware of consequences of elevated phosphate. Twenty-seven percent and thirty-five percent of patients, respectively, had difficulty taking or forgetting to take phosphate binders. Seventy-four percent of patients wanted to know more about CKD-MBD (40% via written material). Of nephrologists surveyed, 76% thought non-compliance with phosphate binders was the main reason for poor control of phosphate (predominantly related to poor patient understanding); 84% thought patients wanted to know more but only 28% provided written material on CKD-MBD. Of dialysis staff surveyed, 63% thought non-compliance with binders explained poor control, the main reason being lack of patient understanding; 88% thought patients wanted to know more but only 17% provided written education.
CONCLUSIONS: Implementation of an intensive educational programme, with a multi-faceted approach, for HD patients may promote better control of CKD-MBD and improve achievement of target levels.

Entities:  

Mesh:

Year:  2010        PMID: 20935019     DOI: 10.1093/ndt/gfq602

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

1.  Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS.

Authors:  Rachel B Fissell; Angelo Karaboyas; Brian A Bieber; Ananda Sen; Yun Li; Antonio A Lopes; Takashi Akiba; Jürgen Bommer; Jean Ethier; Michel Jadoul; Ronald L Pisoni; Bruce M Robinson; Francesca Tentori
Journal:  Hemodial Int       Date:  2015-05-14       Impact factor: 1.812

2.  Multidisciplinary education approach to optimize phosphate control among hemodialysis patients.

Authors:  Meei Wah Chan; Huey Miin Cheah; Madihah Binti Mohd Padzil
Journal:  Int J Clin Pharm       Date:  2019-07-13

3.  Management of mineral metabolism in hemodialysis patients: discrepancy between interventions and perceived causes of failure.

Authors:  Pasquale Esposito; Teresa Rampino; Marilena Gregorini; Carmine Tinelli; Annalisa De Silvestri; Fabio Malberti; Rosanna Coppo; Antonio Dal Canton
Journal:  J Nephrol       Date:  2014-05-08       Impact factor: 3.902

4.  Managing serum phosphate in haemodialysis patients: time for an innovative approach?

Authors:  A Collinson; M McMullan; W Y Tse; H Sadler
Journal:  Eur J Clin Nutr       Date:  2014-01-15       Impact factor: 4.016

5.  Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce?

Authors:  Sophie Liabeuf; Karlijn J Van Stralen; Fergus Caskey; Francesca Tentori; Ronald L Pisoni; Ayesha Sajjad; Kitty J Jager; Ziad A Massy
Journal:  Nephrol Dial Transplant       Date:  2017-10-01       Impact factor: 5.992

6.  Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.

Authors:  Jürgen Floege; Adrian C Covic; Markus Ketteler; Johannes F E Mann; Anjay Rastogi; Bruce Spinowitz; Edward M F Chong; Sylvain Gaillard; Laura J Lisk; Stuart M Sprague
Journal:  Nephrol Dial Transplant       Date:  2015-02-16       Impact factor: 5.992

Review 7.  Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence.

Authors:  Adrian Covic; Anjay Rastogi
Journal:  BMC Nephrol       Date:  2013-07-18       Impact factor: 2.388

8.  A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis.

Authors:  Ramya Bhargava; Philip A Kalra; Paul Brenchley; Helen Hurst; Alastair Hutchison
Journal:  Int J Nephrol       Date:  2015-08-23

9.  Influencing factors for high quality care on postpartum haemorrhage in the Netherlands: patient and professional perspectives.

Authors:  Mallory D Woiski; Evelien Belfroid; Janine Liefers; Richard P Grol; Hubertina C Scheepers; Rosella P Hermens
Journal:  BMC Pregnancy Childbirth       Date:  2015-10-23       Impact factor: 3.007

10.  Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary--results from a nationwide clinical audit.

Authors:  István Kiss; Zoltán Kiss; Csaba Ambrus; András Szabó; János Szegedi; József Balla; Erzsébet Ladányi; Botond Csiky; Ottó Árkossy; Marietta Török; Sándor Túri; Imre Kulcsár
Journal:  BMC Nephrol       Date:  2013-07-18       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.